CILcare
- | Biotech or pharma, therapeutic R&D
- | Diagnostics
Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. Cilcare has a drug pipeline with a lead asset CIL001 transitioning into clinical stage in 2025 in the treatment of Cochlear Synaptopathy.
Cilcare operates from Montpellier, Paris, and Boston and has recently forged a strong partnership with Shionogi in addition to completing a Series A of 40M€.
Address
LexingtonMassachusetts
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}